tbuckley/cabot-search huggingface dataset:
Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population
Authors: Xueli Yang, Jianxin Li, Dongsheng Hu, Jichun Chen, Ying Li, Jianfeng Huang, Xiaoqing Liu, Fangchao Liu, Jie Cao, Chong Shen, Ling Yu, Fanghong Lu, Xianping Wu, Liancheng Zhao, Xigui Wu, Dongfeng Gu
Journal: Circulation (2016)

The accurate assessment of individual risk can be of great value to guiding and facilitating the prevention of atherosclerotic cardiovascular disease (ASCVD). However, prediction models in common use were formulated primarily in white populations. The China-PAR project (Prediction for ASCVD Risk in China) is aimed at developing and validating 10-year risk prediction equations for ASCVD from 4 contemporary Chinese cohorts.Two prospective studies followed up together with a unified protocol were used as the derivation cohort to develop 10-year ASCVD risk equations in 21 320 Chinese participants. The external validation was evaluated in 2 independent Chinese cohorts with 14 123 and 70 838 participants. Furthermore, model performance was compared with the Pooled Cohort Equations reported in the American College of Cardiology/American Heart Association guideline.Over 12 years of follow-up in the derivation cohort with 21 320 Chinese participants, 1048 subjects developed a first ASCVD event. Sex-specific equations had C statistics of 0.794 (95% confidence interval, 0.775-0.814) for men and 0.811 (95% confidence interval, 0.787-0.835) for women. The predicted rates were similar to the observed rates, as indicated by a calibration χ2 of 13.1 for men (P=0.16) and 12.8 for women (P=0.17). Good internal and external validations of our equations were achieved in subsequent analyses. Compared with the Chinese equations, the Pooled Cohort Equations had lower C statistics and much higher calibration χ2 values in men.Our project developed effective tools with good performance for 10-year ASCVD risk prediction among a Chinese population that will help to improve the primary prevention and management of cardiovascular disease.
Rationale for and design of the <scp>TRUE‐AHF</scp> trial: the effects of ularitide on the short‐term clinical course and long‐term mortality of patients with acute heart failure
Authors: Milton Packer, Richard Holcomb, William T. Abraham, Stefan Anker, Kenneth Dickstein, Gerasimos Filippatos, Henry Krum, Aldo P. Maggioni, John J.V. McMurray, Alexandre Mebazaa, Christopher O'Connor, Frank Peacock, Piotr Ponikowski, Frank Ruschitzka, Dirk J. van Veldhuisen, Johannes Holzmeister
Journal: European Journal of Heart Failure (2016)
A Prospective Cohort Study of the Epidemiology of Symptomatic Venous Thromboembolism (VTE) after Isolated Leg Fractures Distal to the Knee without Thromboprophylaxis.
Authors: Rita Selby, William H. Geerts, Mark A. Crowther, Hans J. Kreder, Maurice Bent, Emil Schemitsch, Peter Weiler
Journal: Blood (2005)
High intake of saturated fats is linked to increased risk of heart disease
Authors: Jacqui Wise
Journal: BMJ (2016)

Eating more saturated fatty acids such as those found in cheese, whole milk, butter, beef, and chocolate, is associated with an increased risk of coronary heart disease, a large observational study published in The BMJ has found.1

Researchers from Harvard University, USA, found that a 5% higher intake of longer chain dietary saturated fatty acids was associated with a 25% increased risk of coronary heart disease during 24 to 28 years of follow-up.

The team analysed data from two longitudinal cohort studies: the Health Professionals Follow-Up Study, which included 42 625 men from 1986 …
Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML.
Authors: Christer Paul, Henrik Green, Ingrid Jakobsen Falk, Kourosh Lotfi, Esbjorn Paul, Monika Hermansson, Richard Rosenquist, Kerstin Jonsson-Videsater, Hareth Nahi
Journal: Blood (2009)
Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch.
Authors: Mauricette Michallet, Peter Dreger, Laurent Sutton, Ronald Brand, Sue Richards, Anja van Biezen, Mohamad Sobh, Alois Gratwohl, Karin Kolbe, Claire E. Dearden, Michael Hallek, T. M. de Witte, Dietger W. Niederwieser, Michel Leporrier, Donald Milligan
Journal: Blood (2009)
Low Incidence of Pulmonary Graft-Versus-Host Disease in Older Patients After Reduced Toxicity Conditioning with FBM Prior to Hematopoietic Stem Cell Transplantation.
Authors: Jesus Duque-Afonso, Antje Prasse, Ralph M. Waesch, Hartmut Bertz, Jürgen Finke, Reinhard Marks
Journal: Blood (2009)
Impaired CD163 Mediated Hemoglobin-Scavenging and Hemolytic Crisis in Patients Treated with CD33 Targeted Chemotherapy (Gemtuzumab Ozogamicin, Mylotarg™).
Authors: Maciej B. Maniecki, Henrik Hasle, Lennart Friis-Hansen, Birgitte Lausen, Ove J. Nielsen, Knud Bendix, Soren K. Moestrup, Holger J. Moller
Journal: Blood (2007)
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
Authors: Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield, Magdalena Thurin
Journal: Journal for ImmunoTherapy of Cancer (2016)

Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1). Despite demonstrated successes in a variety of malignancies, responses only typically occur in a minority of patients in any given histology. Additionally, treatment is associated with inflammatory toxicity and high cost. Therefore, determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Although numerous candidate biomarkers have been described, there are currently&nbsp;three FDA-approved assays based on PD-1 ligand expression (PD-L1) that have been clinically validated to&nbsp;identify patients who&nbsp;are more likely to benefit from a&nbsp;single-agent anti-PD-1/PD-L1 therapy. Because of the complexity of the immune response and tumor biology, it is unlikely that a single biomarker will be sufficient to predict clinical outcomes in response to immune-targeted therapy. Rather, the integration of multiple tumor and immune response parameters, such as protein expression, genomics, and transcriptomics, may be necessary for accurate&nbsp;prediction of clinical&nbsp;benefit. Before a candidate biomarker and/or new technology can be used in a clinical setting, several steps are necessary to demonstrate its clinical validity. Although regulatory guidelines provide general roadmaps for the validation process, their applicability to biomarkers in the cancer immunotherapy field is somewhat limited. Thus, Working Group 1 (WG1) of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force convened to address this need. In this two volume series, we discuss pre-analytical and analytical (Volume I) as well as clinical and regulatory (Volume II) aspects of the validation process as applied to predictive biomarkers for cancer immunotherapy. To illustrate the requirements for validation, we&nbsp;discuss examples of biomarker assays that have shown preliminary evidence of an association with clinical benefit from immunotherapeutic interventions. The scope includes only those assays and technologies that have established a certain level of validation for clinical use (fit-for-purpose). Recommendations to meet challenges and strategies to guide the choice of analytical and clinical validation design for specific assays are also provided.
Molecular Heterogeneity in Recombinant Erythropoietin Using Surface Enhanced Laser Induced Desorption Ionization (SELDI). Clinical Implications.
Authors: E. James, J. Maddineni, J. Fareed, M. Florian-Kujawski, F. Baltasar, W. Jeske, D. Hoppensteadt, M. Tobu, M. Demir, O. Iqbal, V. Bansal
Journal: Blood (2005)
Is the Use of 9/10 HLA Unrelated Donors Still Acceptable in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies? Comparison with Transplants From 10/10 HLA Unrelated Donors and Siblings
Authors: Mauricette Michallet, Mohamad Sobh, Stephane Morisset, Marie Y. Detrait, Helene Labussiere, Sophie Ducastelle, Fiorenza Barraco, Jihane Fattoum, Youcef Chelghoum, Xavier Thomas, Franck E. Nicolini
Journal: Blood (2011)
Patients with FLT3 Negative Acute Myeloid Leukemia and Normal Cytogenetic who Have the Combination Mutations (NPM1-/CEBPA-) Have Better Survival Than Patients Who Have the Combination Mutations (NPM1+/CEBPA+)
Authors: Shamail Butt, Pascal Akl, Himanshu Bhardwaj, Samer A Srour, Terry Dunn, Shubham Pant, Mohamad Ali Cherry
Journal: Blood (2011)
Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor
Authors: Efstathios Kastritis, Evangelos Terpos, Maria Gavriatopoulou, Chrysanthi Skevaki, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Marianna Politou, Ioannis Papassotiriou, Meletios A. Dimopoulos
Journal: Blood (2014)
Danapaloid Is Significantly Effective for the Prophylaxis of Hepatic Veno-Occlusive Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of 85 Children with Hematological Malignancies.
Authors: Hirotoshi Sakaguchi, Sayoko Doisaki, Nao Yoshida, Hideki Muramatsu, Nobuhiro Watanabe, Kimikazu Matsumoto, Koji Kato
Journal: Blood (2008)
High Transgene Expression Rates After Extended Follow up Among Rhesus Macaque Recipients of Autologous Hematopoietic Stem Cells Transduced with a Modified HIV1-Based Lentiviral Vector
Authors: Naoya Uchida, Phillip W. Hargrove, Coen J. Lap, Oswald Phang, Aylin C. Bonifacino, Allen E. Krouse, Mark E. Metzger, Anh-Dao Nguyen, Matthew M. Hsieh, Tyra G. Wolfsberg, Robert E. Donahue, Derek A. Persons, John F. Tisdale
Journal: Blood (2011)
Local and transient gene expression primes the liver to resist cancer metastasis
Authors: Tyler J. Goodwin, Yingqiu Zhou, Sara N. Musetti, Rihe Liu, Leaf Huang
Journal: Science Translational Medicine (2016)

Targeted nanoparticles induce expression of a CXCL12/SDF-1 trap in a transient and liver-specific manner to inhibit colorectal cancer liver metastasis.
An Integrative Network Approach for Genomic Discovery and Personalized Therapy in Relapsed Multiple Myeloma
Authors: Ben Readhead, Krishan Kania, Caroline Eden, Deepak Perumal, Vickram Gidwani, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Pei-Yu Kuo, Brian Kidd, Joel Dudley, Samir Parekh
Journal: Blood (2014)
IL-10-592 Polymorphism Predicts the Clinical Outcome of Japanese Patients with Multiple Myeloma and MGUS.
Authors: Tetsuhiro Kasamatsu, Takayuki Saitoh, Hiroshi Handa, Takafumi Matsushima, Norifumi Tsukamoto, Masamitsu Karasawa, Hatsue Ogawara, Morio Sawamura, Yohihisa Nojima, Hirokazu Murakami
Journal: Blood (2007)
SAT0639-HPR The Most Frequent Inquiries of Patients on Subcutaneous anti -TNF Alpha Therapies: Table 1.
Authors: M. Pavic Nikolic, A. Hocevar
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Subcutaneous TNFα blockers enable patients with inflammatory arthritis to better control their disease and subsequently improve the quality of their daily functioning. At our Department of Rheumatology trained nurses provide education about proper subcutaneous (s.c.) administration techniques and telephone counseling about different issues asked by patients concerning their treatment. One of the key components of patient education and counseling is to explain when to postpone the biologic therapy in case of infection or planned surgical procedure. <h3>Objectives</h3> The aim of our study was to look at the most frequent questions raised by patients about their treatment. In addition we looked at a potential association between particular patient problem and specific subcutaneous TNFα blocker. <h3>Methods</h3> Data was collected between January 2013 and May 2014 and included demographic data, prescribed anti-TNF drug, and description of the patient reported query regarding their s.c. anti-TNF treatment. Patient queries were grouped into six topics: skin reactions, infections, vaccinations, drug interactions, planned surgical procedures and other (Table 1). Appropriate statistical methods were used to analyze data. <h3>Results</h3> During the observation period 98 patients (23% males, mean (SD) age 56.1 (13.9) years) treated with subcutaneous TNFα blocker asked for help using a telephone call. Patients were treated with the following s.c. anti-TNF drugs: certolizumab (9%), etanercept (27%), adalimumab (41%), and golimumab (23%). The most common patient problems on subcutaneous TNFα inhibitors are presented in Table 1. In 22% of cases patients seeked telephone advice for other different health problems (swollen joints, drug ineffectiveness, potential adverse effects).We did not find any significant difference concerning particular TNFα blocker and the pertinent patient problem. <h3>Conclusions</h3> Telephone assistance is valuable for patients. Patients request more information about their treatment and continuous patient education could improve outcomes in the management of inflammatory rheumatic diseases. <h3>Disclosure of Interest</h3> None declared
Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
Authors: Jesus G. Berdeja, Paul G. Richardson, Sagar Lonial, Ruben Niesvizky, Ai-Min Hui, Deborah Berg, Neeraj Gupta, Guohui Liu, Alessandra Di Bacco, Shaji Kumar
Journal: Blood (2011)
Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115
Authors: Vaishali Sanchorawala, Antje Hoering, David C Seldin, Kathleen T Finn, Salli A Fennessey, Bassam I Mattar, Hana F Safah, Leona Holmberg, Robert M. Dean, Robert Z. Orlowski, Bart Barlogie
Journal: Blood (2011)
The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.
Authors: Franck E Nicolini, Sandrine Hayette, Lila Gilis, Madeleine Etienne, Elodie Gadolet, Isabelle Tigaud, Helene Labussiere, Luc Gerland, Damien Waz, Mohamad Sobh, Stephane Morisset, Mauricette Michallet
Journal: Blood (2010)
Reduced Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor.
Authors: Navneet S. Majhail, Claudio Brunstein, John E. Wagner, Marcie Tomblyn, Avis Thomas, Jeffrey S. Miller, Mukta Arora, Dan S. Kaufman, Linda J. Burns, Arne Slungaard, Philip B. McGlave, Daniel J. Weisdorf
Journal: Blood (2007)
Gleevec Resistant Activating Mutation of c-Kit (D816V) Demonstrates Ligand Independent Growth and Promiscuous Cooperation with Multiple Cytokine Receptors Via the p85α Subunit of Class IA PI-3Kinase.
Authors: Veerendra Munugalavadla, Emily Sims, Jovencio Borneo, Reuben Kapur
Journal: Blood (2005)
石灰化病変の経皮的末梢血管インターベンションのための新しいコンセプト:石灰化アテロームと拡大における侵襲的ワイヤ再疎通(ARCADIA)法
Authors: Yokota Daisuke, Nasu Kenya, KO Yoshihiro, Itoh Tsuyoshi, Kodama Atsuko, Habara Maoto, Kurita Tairo, Teramoto Tomohiko, Tanaka Nobuyoshi, Kimura Masashi, Itoh Tatsuya, Kinoshita Yoshihisa, Ehara Mariko, Tsuchikane Etsuo, Asakura Keiko, Terashima Mitsuyasu, Asakura Yasushi, Katoh Osamu, Suzuki Takahiko
Journal: Circulation (2012)
Erythroid Cells Adapt to L-Leucine Scarcity By Reducing Hemoglobin Production Via the mTORC1/4E-BP Pathway
Authors: Jacky Chung, Daniel E. Bauer, Alireza Ghamari, Christopher P. Nizzi, Kathryn M. Deck, Paul D. Kingsley, Yvette Y. Yien, Nicholas C. Huston, Caiyong Chen, Johannes G. Wittig, James Palis, Stuart H. Orkin, Harvey F. Lodish, Richard S. Eisenstein, Alan B. Cantor, Barry H. Paw
Journal: Blood (2014)
P72 Baseline data from the rosa trial: a randomised controlled trial of the effect of CPAP on diabetic macular oedema in people with concurrent obstructive sleep apnoea
Authors: SD West, J Hughes, B Prudon
Journal: Thorax (2016)

The ROSA trial (Retinopathy and Obstructive Sleep Apnoea) is a multi-centre randomised controlled trial conducted in the United Kingdom. The hypothesis is that CPAP (continuous positive airway pressure) will improve visual acuity in people with diabetic macular oedema and concurrent OSA, due to improvements in intermittent hypoxia, blood pressure and catecholamine surges. An uncontrolled study showed visual acuity improved equivalent to one line on the logMAR chart in those people who used CPAP regularly at six months (Mason RH <i>et al</i>. <i>Respiration</i> 2012). We present baseline data from a larger randomised controlled trial. <h3>Methods</h3> Patients of Eye Hospitals across the UK with diabetic macular oedema and type 2 diabetes were offered home sleep studies to diagnose OSA. These were posted to them with instructions by the coordinating centre and returned by post after a single night’s recording. Those patients found to have severe OSA (ODI &gt; 20 or AHI &gt; 30), along with visual impairment due to diabetic macular oedema were randomised to usual ophthalmic care (control) or usual ophthalmic care plus CPAP for one year. Anyone with respiratory failure, excessive daytime sleepiness requiring urgent treatment or cataract precluding ophthalmic assessment was excluded. Follow up occurred at three, six and twelve months and included measures of sleepiness, health related quality of life, visual acuity, optical coherence tomography and retinal photography. <h3>Results</h3> There have been 130 patients randomised from 23 UK centres; 64 to CPAP, 66 to control. The groups are well matched at baseline (Table). <h3>Conclusions</h3> This novel study demonstrates that it is feasible to conduct a multicentre randomised controlled trial with UK Eye Hospitals and their local Sleep service, all coordinated by a single centre (Newcastle). The UK NHS National Institute for Health Research has facilitated this research via the Local Clinical Research Network at each centre. Minimisation criteria for randomisation has enabled the two groups to be well matched at baseline, essential for this type of study. The results of this trial will determine whether CPAP could form a novel treatment for diabetic macular oedema and and visual impairment in people with concurrent obstructive sleep apnoea; these results are eagerly awaited when follow up is completed in 2017.
FRI0563 It's More than Dryness and Fatigue: The Patient Perspective on Health-Related Quality of Life in Primary Sjögren Syndrome - A Qualitative Study
Authors: A. Lackner, A. Ficjan, J. Unger, W. Graninger, C. Dejaco
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with primary Sjögren Syndrome (PSS) are affected by glandular and extraglandular manifestations leading to physical and mental impairment. How these factors affect the health related quality of life (HRQL) of these patients is largely unexplored. <h3>Objectives</h3> This qualitative study was conducted to investigate patients9 perspectives and needs influencing HRQL in PSS. <h3>Methods</h3> We recruited 20 consecutive PSS patients fulfilling the American-European consensus classification criteria out of the PSS cohort of the Medical University Graz, Austria. A total of 6 focus group sessions were performed. A discussion guide with four open-ended questions was developed containing all elementary components of HRQL (physical, mental, social, daily life). All interviews were audio-recorded and transcribed verbatim. A modified meaning condensation procedure was used to analyse the data. <h3>Results</h3> All patients were female, the mean age was 61 (SD ±8) years and mean disease duration was 5 (±2) years. The focus group sessions took on average 58 ±13 minutes. The number of patients in each group ranged from three to four. The interview analysis resulted in 484 meaning units, 254 subconcepts and 87 concepts. The identified concepts were grouped into three dimensions: physical dimension, psychological &amp; emotional challenges and social life &amp; daily living. An inter-dependency of the three dimensions was identified. The concepts most commonly reported belonged to the physical dimension: pain, dryness and complaints related to these two symptoms. Patients frequently mentioned consequences of dryness including recurrent inflammation of eyes and ears, loss of sense of smell and taste, sleeping disturbances and the inability to eat and chew. In the dimension psychological &amp; emotional challenges, the most frequently mentioned concepts were "being worried about the future", "a long symptom to diagnosis lag" and "the feeling of being an encumbrance for their families". Concepts like dependency on relatives in daily life, difficulties at work and financial burden were classified within the dimension of social life &amp; daily living. <h3>Conclusions</h3> We found that three interrelated dimensions (physical dimension, psychological &amp; emotional challenges and social life &amp; daily living) best reflected patients9 experiences and feelings related to PSS. HRQL in PSS patients was influenced not only by dryness rather psychological and social burden clearly impacted the patients. <h3>Disclosure of Interest</h3> None declared
A novel codon-based de Bruijn graph algorithm for gene construction from unassembled transcriptomes
Authors: Gongxin Peng, Peifeng Ji, Fangqing Zhao
Journal: Genome biology (2016)

Most gene prediction methods detect coding sequences from transcriptome assemblies in the absence of closely related reference genomes. Such methods are of limited application due to high transcript fragmentation and extensive assembly errors, which may lead to redundant or false coding sequence predictions. We present inGAP-CDG, which can construct full-length and non-redundant coding sequences from unassembled transcriptomes by using a codon-based de Bruijn graph to simplify the assembly process and a machine learning-based approach to filter false positives. Compared with other methods, inGAP-CDG exhibits a significant increase in predicted coding sequence length and robustness to sequencing errors and varied read length.
Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494).
Authors: Vicki A. Morrison, Edie A. Weller, Thomas M. Habermann, Shuli Li, Sandra J. Horning, Richard I. Fisher, Bruce A. Peterson
Journal: Blood (2004)
Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B
Authors: Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Noritomo Shimada, Koichi Takaguchi, Tomonori Senoh, Kunihiko Tsuji, Yoshihiko Tachi, Atsushi Hiraoka, Toru Ishikawa, Toshihide Shima, Takeshi Okanoue
Journal: Journal of Hepatology (2016)
Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,
Authors: Sabine Ponader, Sriram Balasubramanian, Lan V Pham, Jun Chen, Archito T. Tamayo, Michael Wang, Susan O'Brien, William G. Wierda, Michael J Keating, Richard J. Ford, Jan A. Burger
Journal: Blood (2011)